Anidulafungin

Title: Anidulafungin
CAS Registry Number: 166663-25-8
CAS Name: 1-[(4R,5R)-4,5-Dihydroxy-N2-[[4¢¢-(pentyloxy)[1,1¢:4¢,1¢¢-terphenyl]-4-yl]carbonyl]-L-ornithine]echinocandin B
Additional Names: V-echinocandin
Manufacturers' Codes: LY-303366; VER-002
Molecular Formula: C58H73N7O17
Molecular Weight: 1140.24
Percent Composition: C 61.09%, H 6.45%, N 8.60%, O 23.85%
Literature References: Semisynthetic echinocandin antifungal; inhibits 1,3-b-D-glucan synthase. Prepn: F. J. Burkhardt et al., EP 561639 (1993 to Lilly); M. Debono et al., J. Med. Chem. 38, 3271 (1995). HPLC determn in plasma: L. L. Zornes, R. E. Stratford, J. Chromatogr. B 695, 381 (1997). Comparative in vitro susceptibility: M. A. Pfaller et al., Diagn. Microbiol. Infect. Dis. 30, 251 (1998); M. Cuenca-Estrella et al., J. Antimicrob. Chemother. 46, 475 (2000). Pharmacokinetics and antifungal activity: A. H. Groll et al., Antimicrob. Agents Chemother. 45, 2845 (2001). Clinical evaluation in invasive candidiasis: M. A. Pfaller et al., ibid. 49, 4795 (2005). Review of clinical experience: M. A. Pfaller, Expert Opin. Invest. Drugs 13, 1183-1197 (2004); of pharmacology: J. A. Vazquez, Clin. Ther. 27, 657-673 (2005).
Therap-Cat: Antifungal.
Keywords: Antifungal (Antibiotics); Echinocandins.
Anilazine Anileridine Aniline Aniline Mustard Anilinephthalein

Anidulafungin
Anidulafungin structure.svg
Systematic (IUPAC) name
N-[(3S,6S,9S,11R,15S,18S,20R,21R,24S,25S,26S)-6-[(1S,2R)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-11,20,21,25-tetrahydroxy-3,15-bis[(1R)-1-hydroxyethyl]-26-methyl-2,5,8,14,17,23-hexaoxo-1,4,7,13,16,22-hexaazatricyclo[22.3.0.09,13]heptacosan-18-yl]- 4-{4-[4-(pentyloxy)phenyl]phenyl}benzamide
Clinical data
Trade names Eraxis
AHFS/Drugs.com monograph
Legal status  ?
Pharmacokinetic data
Protein binding 84 %
Half-life 40–50 hours
Identifiers
CAS number 166663-25-8 YesY
ATC code J02AX06
PubChem CID 166548
DrugBank DB00362
ChemSpider 21106258 YesY
UNII 9HLM53094I YesY
KEGG D03211 N
ChEMBL CHEMBL1630215 N
Chemical data
Formula C58H73N7O17 
Mol. mass 1140.24 g/mol
 N (what is this?)  (verify)

Anidulafungin or Eraxis (Ecalta in Europe) is a semisynthetic echinocandin used as an antifungal drug. Anidulafungin was originally manufactured and submitted for FDA approval by Vicuron Pharmaceuticals.[1] Pfizer acquired the drug upon its acquisition of Vicuron in the fall of 2005.[2] Pfizer gained approval by the Food and Drug Administration (FDA) on February 21, 2006;[3] it was previously known as LY303366. There is preliminary evidence it has a similar safety profile to caspofungin. Anidulafungin has proven efficacy against esophageal candidiasis, but its main use will probably be in invasive Candida infection;[4][5][6] it may also have application in treating invasive Aspergillus infection. It is a member of the class of antifungal drugs known as the echinocandins; its mechanism of action is by inhibition of (1→3)-β-D-glucan synthase, an enzyme important to the synthesis of the fungal cell wall.